219 related articles for article (PubMed ID: 18359865)
21. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Karavasilis V; Kotoula V; Pentheroudakis G; Televantou D; Lambaki S; Chrisafi S; Bobos M; Fountzilas G
J Neurol; 2013 Jun; 260(6):1469-80. PubMed ID: 23292205
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
Pollack IF; Jakacki RI; Blaney SM; Hancock ML; Kieran MW; Phillips P; Kun LE; Friedman H; Packer R; Banerjee A; Geyer JR; Goldman S; Poussaint TY; Krasin MJ; Wang Y; Hayes M; Murgo A; Weiner S; Boyett JM
Neuro Oncol; 2007 Apr; 9(2):145-60. PubMed ID: 17293590
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Nghiemphu PL; Wen PY; Lamborn KR; Drappatz J; Robins HI; Fink K; Malkin MG; Lieberman FS; DeAngelis LM; Torres-Trejo A; Chang SM; Abrey L; Fine HA; Demopoulos A; Lassman AB; Kesari S; Mehta MP; Prados MD; Cloughesy TF;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1422-7. PubMed ID: 20934264
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R
J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters KB; Sathornsumetee S; Threatt S; Sampson JH; Herndon JE; Coan A; McSherry F; Rich JN; McLendon RE; Zhang S; Friedman HS
J Neurooncol; 2012 Jul; 108(3):499-506. PubMed ID: 22407177
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Newlands ES; Foster T; Zaknoen S
Br J Cancer; 2003 Jul; 89(2):248-51. PubMed ID: 12865911
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
J Clin Oncol; 2009 Mar; 27(8):1262-7. PubMed ID: 19204199
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
32. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Dresemann G; Weller M; Rosenthal MA; Wedding U; Wagner W; Engel E; Heinrich B; Mayer-Steinacker R; Karup-Hansen A; Fluge O; Nowak A; Mehdorn M; Schleyer E; Krex D; Olver IN; Steinbach JP; Hosius C; Sieder C; Sorenson G; Parker R; Nikolova Z
J Neurooncol; 2010 Feb; 96(3):393-402. PubMed ID: 19688297
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Grimm SA; Marymont M; Chandler JP; Muro K; Newman SB; Levy RM; Jovanovic B; McCarthy K; Raizer JJ
J Neurooncol; 2012 Nov; 110(2):237-43. PubMed ID: 22875709
[TBL] [Abstract][Full Text] [Related]
34. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Chew HK; Barlow WE; Albain K; Lew D; Gown A; Hayes DF; Gralow J; Hortobagyi GN; Livingston R
Clin Breast Cancer; 2008 Dec; 8(6):511-5. PubMed ID: 19073506
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Al-Batran SE; Atmaca A; Schleyer E; Pauligk C; Hosius C; Ehninger G; Jäger E
Cancer; 2007 May; 109(9):1897-904. PubMed ID: 17377918
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
39. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Dugan E; Truax R; Meadows KL; Nixon AB; Petros WP; Favaro J; Fernando NH; Morse MA; Blobe GC; Hurwitz HI
Anticancer Res; 2010 Apr; 30(4):1251-6. PubMed ID: 20530436
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
